Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | BRAF V600E |
| Therapy | Afatinib + Encorafenib |
| Indication/Tumor Type | colorectal cancer |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| BRAF V600E | colorectal cancer | sensitive | Afatinib + Encorafenib | Preclinical - Cell culture | Actionable | In a preclinical study, Gilotrif (afatinib) and Braftovi (encorafenib) combination treatment suppressed Egfr, Mek, and Erk activation more efficiently than either agent alone, and synergistically inhibited viability and colony formation in cell lines derived from the peritoneal lavage of a microsatellite stable (MSS) colorectal cancer mouse model harboring BRAF V600E along with TP53 R172H (corresponding to R175H in human) and APC loss in culture (PMID: 41566838). | 41566838 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (41566838) | Novel Syngeneic Cell Lines for Studying High-Risk BRAFV600E-Driven Colorectal Cancer In Vivo. | Full reference... |